Chondroitinase and Growth Factors Enhance Activation and Oligodendrocyte Differentiation of Endogenous Neural Precursor Cells after Spinal Cord Injury by Karimi-Abdolrezaee, Soheila et al.
Chondroitinase and Growth Factors Enhance Activation
and Oligodendrocyte Differentiation of Endogenous




2, Michael G. Fehlings
2,3
1Regenerative Medicine Program and Department of Physiology, University of Manitoba, Winnipeg, Canada, 2Toronto Western Research Institute, Toronto, Canada,
3Department of Surgery and Neuroscience Program, University of Toronto, Toronto, Canada
Abstract
The adult spinal cord harbours a population of multipotent neural precursor cells (NPCs) with the ability to replace
oligodendrocytes. However, despite this capacity, proliferation and endogenous remyelination is severely limited after
spinal cord injury (SCI). In the post-traumatic microenvironment following SCI, endogenous spinal NPCs mainly differentiate
into astrocytes which could contribute to astrogliosis that exacerbate the outcomes of SCI. These findings emphasize a key
role for the post-SCI niche in modulating the behaviour of spinal NPCs after SCI. We recently reported that chondroitin
sulphate proteoglycans (CSPGs) in the glial scar restrict the outcomes of NPC transplantation in SCI by reducing the survival,
migration and integration of engrafted NPCs within the injured spinal cord. These inhibitory effects were attenuated by
administration of chondroitinase (ChABC) prior to NPC transplantation. Here, in a rat model of compressive SCI, we show
that perturbing CSPGs by ChABC in combination with sustained infusion of growth factors (EGF, bFGF and PDGF-AA)
optimize the activation and oligodendroglial differentiation of spinal NPCs after injury. Four days following SCI, we
intrathecally delivered ChABC and/or GFs for seven days. We performed BrdU incorporation to label proliferating cells
during the treatment period after SCI. This strategy increased the proliferation of spinal NPCs, reduced the generation of
new astrocytes and promoted their differentiation along an oligodendroglial lineage, a prerequisite for remyelination.
Furthermore, ChABC and GF treatments enhanced the response of non-neural cells by increasing the generation of new
vascular endothelial cells and decreasing the number of proliferating macrophages/microglia after SCI. In conclusions, our
data strongly suggest that optimization of the behaviour of endogenous spinal NPCs after SCI is critical not only to promote
endogenous oligodendrocyte replacement, but also to reverse the otherwise detrimental effects of their activation into
astrocytes which could negatively influence the repair process after SCI.
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Introduction
Spinal cord injury (SCI) results in limited spontaneous axonal
remyelination [1,2,3] despite the existence of multipotent endog-
enous spinal neural precursor cells (esNPCs) with the potential to
replace lost oligodendrocytes [4,5,6,7]. Although increasing
evidence demonstrates that SCI triggers the proliferation of
esNPCs in the ependymal layer [6,8,9,10,11], the outcome of this
activity does not result in a sizable and meaningful oligodendrog-
lial differentiation and maturation following SCI. Activated
esNPCs from the ependymal region predominantly differentiate
into astrocytes after SCI and generation of oligodendrocytes
essential for remyelination is very limited [6,7,10,12]. The newly
generated astrocytes migrate to the site of injury, become reactive
and contribute to astrogliosis after SCI [10,13]. This evidence
suggests that the cell replacement potential of esNPCs is negatively
influenced by their post SCI-environment. Optimization of the
behaviour of esNPCs after SCI is important not only to promote
endogenous oligodendrocyte replacement, but also to reverse the
otherwise non-constructive effects of their activation in generating
glial scar and inhibiting repair and regeneration after SCI.
Following SCI, neuroinflammation and reactive astrogliosis
profoundly modify the extracellular matrix (ECM) and foster the
generation of an inhibitory environment to neural repair and
regeneration [14]. Chondroitin sulfate proteoglycans (CSPGs) are
up-regulated in the ECM around the SCI lesion and exert
significant inhibitory effects on spinal cord regeneration and
plasticity [15,16,17,18,19]. In a rat model of chronic compressive
SCI, we have recently shown that the up-regulation of CSPGs
potently limit the survival, integration and migration of trans-
planted adult NPCs [18]. When we targeted CSPGs with
Chondroitinase ABC (ChABC) at chronic stages of SCI and prior
to NPC transplantation, it significantly enhanced the survival,
mobilization and integration of engrafted NPCs within the
chronically injured spinal cord [18]. The effects of ChABC was
furthered enhanced by combining ChABC with the transient
administration of a cocktail of growth factors that included
epidermal growth factor (EGF), basic fibroblast growth factor
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e37589(bFGF) and platelet derived growth factor-AA (PDGF-AA) [18].
The combined effects of ChABC and growth factors enhanced the
long-term survival of transplanted NPCs and directed their
differentiation along an oligodendroglial lineage associated with
remyelination and functional recovery in a chronic model of SCI
[18].
In the present study, we addressed whether optimizing the
injury microenvironment with combination of ChABC and the
growth factors (GFs) would promote the regenerative response of
esNPCs early after SCI. Here, we show for the first time that
perturbing CSPGs and increasing the bioavailability of key growth
factors required for the expansion of NPCs significantly improved
the proliferation of esNPCs and decreased their differentiation into
astrocytes which was also accompanied by reduced inflammation
and reactive astrogliosis and increased generation of new
endothelial cells in the injured spinal cord. Importantly, combined
effects of ChABC and GFs enhanced oligodendroglial differenti-
ation of esNPCs after SCI. These results suggest that optimizing
the inhibitory microenvironment for spinal cord precursor cells is a
promising regenerative approach for SCI, which offers a potential
alternative or complementary approach to cell transplantation.
Methods
Animals and Animal Care
All experimental protocols were approved by the Animal
Committee of the University of Manitoba and the University
Health Network in accordance with the policies established in the
guide to the care and use of experimental animals prepared by the
Canadian Council of Animal Care. A total of 55 adult female
Wistar rats (250 g; Charles River Laboratories, Quebec, Canada)
were used in this study. Animals were housed in standard plastic
cages at 22uC before spinal cord injury (SCI) and 26uC after SCI
in a 12:12 h light/dark photoperiod. Pelleted food and drinking
water were available ad libitum. Hardwood sawdust bedding was
used before SCI and then was replaced by soft paper bedding after
SCI to prevent skin lesion. After surgeries, animals were given
buprenorphine (Temgesic, 0.05 mg/kg) three times every 8 hrs to
manage pain and discomfort. SCI rats were examined daily and
the bladder was expressed three times daily until the recovery of
spontaneous bladder function.
Table 1. Antibodies.
Antibody Specificity Source Dilution factor
BrdU Proliferating cells that have incorporated BrdU in S phase Serotec (Rat, OBT0030G) 1:400
Nestin Neural stem/progenitor cells Chemicon (Mouse, MAB353) 1:200
GFAP astrocytes Chemicon (Mouse, MAB360) 1:800
GFAP astrocytes Chemicon (Rabbit, AB5804) 1:1000
CS56 CSPGs Sigma (Mouse, C8035) 1:200
C4S Chondroitin 4 sulphate Chemicon (Mouse, MAB2030) 1:200
OX42 Macrophages/microglia Serotec (Mouse, MCA275G) 1:50
Iba-1 Macrophages/microglia Wako (Rabbit, 019-19741) For immunostaining 1:500
Iba-1 Macrophages/microglia Wako (Rabbit, 016-20001) For immunoblotting 1:1000
Olig2 Oligodendrocyte progenies Chemicon (Rabbit, AB9610) 1:1000
NG2 Oligodendrocyte precursor cells Chemicon (Rabbit, AB5320) 1:200
NG2 Oligodendrocyte precursor cells Chemicon (Mouse, MAB5384) 1:200
APC (CC1) Mature oligodendrocytes Calbiochem (Mouse, OP80) 1:50
Reca-1 Endothelial cells Serotec (Mouse, MCA970R) 1:25
Actin cytoskeleton filament (housekeeping protein) Chemicon (Mouse, MAB1501R) 1:300
doi:10.1371/journal.pone.0037589.t001
Table 2. Summary of triple immunolabeling cell quantifications.
Multiple labelling combinations Cell type and criteria for cell counting
Nestin/GFAP/BrdU Nestin+/GFAP+/BrdU+: considered as astrocyte
Nestin2/GFAP+/BrdU+: considered as astrocytes
Nestin+/GFAP2/BrdU+: considered as NPCs
Olig2/GFAP/BrdU Olig2+/GFAP+/BrdU+: considered as astrocytes
Olig2+/GFAP2/BrdU+: considered as oligodendrocyte progenies
Olig2/NG2/BrdU Olig2+/NG2+/BrdU+: considered as oligodendrocyte precursors
Olig2/APC/BrdU Olig2+/APC+/BrdU+: considered as mature oligodendrocyte
Reca-1/NG2/BrdU Reca-1+/NG2+/BrdU+: considered as endothelial cells
Iba-1/NG2/BrdU Iba-1+/NG2+/BrdU+: considered as macrophages/microglia
doi:10.1371/journal.pone.0037589.t002
Activating Endogenous Precursor Cells after Injury
PLoS ONE | www.plosone.org 2 May 2012 | Volume 7 | Issue 5 | e37589Rat Compressive Thoracic Spinal Cord Injury Model
We used an aneurysm clip compression model of SCI that has
been extensively characterized and used by our group
[1,18,20,21,22,23]. All surgeries were performed under aseptic
conditions and using general gas anesthesia consisting of a mixture
of O2/isoflurane (1–4%) given through a mask integrated in a
surgical stereotaxic frame. The surgical area was shaved and
disinfected with 70% ethanol and betadine. A midline incision was
made at the thoracic area (T4–T9) and skin and superficial
muscles were retracted. The rats underwent a T6–T8 laminecto-
my and then, received a 23 g clip (Walsh Inc., Oakville, Ontario,
Canada) compression injury for 1 min at the level of T7 of the
spinal cord. The surgical wounds were sutured and the animals
were given postoperative analgesia (Temgesic, 50 mg/kg) and
saline (0.9%; 5 ml) to prevent pain and dehydration. Animals
received Clavamox (Amoxicillin plus Clavulanic Acid, Pfizer
Animal Health) for 5 days. The model characterization, histolog-
ical assessment of injury and behavioral assessment have been
characterized extensively by our group [1,18,20,21,24].This model
of SCI in the rat accurately mimics the key features of human SCI.
It creates a model of moderately severe SCI, which results in a
central cavitation and loss of 80% of axons in the spinal cord white
matter (Fehlings and Tator, 1995), demyelination of the surviving
axons in the residual white matter as well as unmyelinated axons
in the injured spinal cord and behavioral evidence of a spastic
paraparesis (Nashmi et al., 1997; Nashmi and Fehlings, 2001).
Collectively, the outcome of this model is of relevance to the
majority of patients with severe, incomplete SCI.
Experimental Groups and Treatments
Before SCI, rats were randomly allocated into four experimen-
tal groups to receive either vehicle or ChABC and/or growth
factor treatments. The experimental groups included: 1) Injured-
vehicle (receiving vehicle containing saline plus 0.1% rat serum
albumin), 2) Injured-ChABC (receiving chondroitinase ABC,
5 U/ml in vehicle, Seikagaku Corporation, Tokyo, Japan), 3)
Injured-Growth Factors (a GFs cocktail containing including
PDGF-AA (Sigma, 1 mg/100 ml), bFGF (Sigma, 3 mg/100 ml) and
Figure 1. Representative images of compressive SCI in rats at 12 days post-injury. (A) Images of thoracic spinal cord cross sections at
various rostral and caudal distances to the injury center were counter-stained with Luxol Fast Blue (LFB) and hematoxylin/eosin (H&E). We found the
presence of an intact central canal (CC) at around 2.5 mm away from the injury center in all rats. (B) Magnified area in the box in (A) show the
ependymal layer that lines the central canal. (C-D) Confocal images of the central canal immunostained for vimentin.
doi:10.1371/journal.pone.0037589.g001
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ChABC+GFs (receiving the combination of ChABC and GFs in
vehicle). A summary of our experimental approaches and groups is
depicted in Table S1.
Administration of treatments. At four days post SCI, the
injured rats were anesthetized using isoflurane inhalation (1–2%)
and a 1:1 mixture of O2/N2O and then the injured spinal cord
was carefully re-exposed using microsurgical techniques. Treat-
ments were administered intrathecally using a fine catheter (Alzet,
Rat IT, 0007741, 0.36 mm OD; 0.18 mm ID) connected to an
osmotic mini-pump (Alzet pump model No.1007D, 0.5 ml/hr) for
7 days as we reported previously [18,21]. The catheter was
securely inserted in the subarachnoid space around the injured
area.
BrdU incorporation regimen. To examine the proliferation
kinetics and fate of the mitotically active cells in the injured spinal
cord after treatments, all rats received 5-Bromo-2-deoxyuridine
(BrdU, IP, 50 mg/kg) injections starting on the treatment day.
The rats received two daily injections of BrdU and a last one at 2
hours before euthanasia for a of total 15 injections.
Euthanasia/tissue Processing
Seven days after treatments (12 days post-SCI), rats in all
treatment groups were deeply anesthetized with isoflurane
inhalation and then perfused transcardially with cold PBS
(0.1 M) followed by 4% paraformaldehyde (PFA) in 0.1 M PBS,
pH 7.4. A 3 cm length of the spinal cord centered at the injury
center was dissected and postfixed in the perfusing solution plus
10% sucrose overnight at 4uC, and then cryoprotected in 20%
sucrose in PBS for 48 h at 4uC. Then, the spinal cord centered at
the injury site was dissected and embedded in mounting media
(HistoPrep, Fisher Scientific) on dry ice. Cryostat sections (25 mm)
were cut and stored at -70uC.
Histological Assessment of SCI Lesion
To examine the spinal cord lesion and determine the epicenter
of SCI, we used Luxol Fast Blue (LFB) and hematoxylin-eosin
(HE). Tissue sections displaying the largest proportion of tissue
disintegration compared with total cross-sectional area were taken
to represent the epicentre of the injury.
Immunohistochemical Procedures and Image Analysis
For all immunohistochemical staining, the blocking solution
contained 5% non-fat milk, 1% BSA, and 0.3% Triton X-100 in
0.1 M PBS unless otherwise has been mentioned.
Immunodetection of GFAP, CSPGs, and C4S-DS. The
frozen slides were air dried at room temperature for 20 min and
then were washed with PBS for 10 min. The sections were blocked
and then incubated with primary antibodies. The following
primary antibodies were used overnight at 4uC: rabbit anti-GFAP
(1:1000, Millipore Bioscience Research Reagents) for astrocytes,
mouse anti-CSPGs (CS56, Sigma, 1:200), mouse anti-chondroitin-
4-sulfate (C4S, 1:200, Millipore Bioscience Research Reagents) for
visualization of CSPG GAG digestion. The slides were washed in
PBS three times and then incubated with fluorescent Alexa 568 or
488 or 647 goat-anti mouse secondary antibodies (Invitrogen,
1:400) for 1 h. The slides were coverslipped with Mowiol
mounting medium containing DAPI to counterstain the nuclei.
The images were taken using a Zeiss 510 laser confocal
microscope or Leica epifluorescence microscope.
For immunoblotting, spinal cords were dissected, placed in ice-
cold artificial CSF (124 mM NaCl, 3 mM KCl, 1 mM NaHPO4,
26 mM NaHCO3, 1.5 mM MgSO4, 1.5 mM CaCl2, and 10 mM
glucose), and cleaned from meninges and nerve roots. One
centimeter of the cord centered at the injury site was dissected and
homogenized (in a buffer composed of 50 mM Tris-HCl, pH 7.4,
1 mM EDTA, 0.1% SDS, 100 mM leupeptin, 1 mM pepstatin,
10 mg/ml aprotinin, and 100 mM phenylmethylsulfonyl fluoride).
For slot blotting, 3 mg of protein/well was transferred to
polyvinylidene difluoride membranes (Millipore) using Bio-Dot
slot blot apparatus (Bio-Rad) according to the manufacturer’s
instructions. The membranes were then incubated with mouse
anti-CSPGs (CS-56, 1:300, Sigma), mouse anti-GFAP (MAB360,
Chemicon, 1:5000), mouse anti-C4S (Chemicon, 1:200) and rabbit
anti-Iba1 (016-20001, Wako, 1:1000). Following the incubation
with HRP-conjugated goat anti-mouse antibody (1:5000), mem-
branes were incubated in ECL plus immunoblotting detection
reagents (GE Healthcare) according to the manufacturer’s
specifications. Immunoreactive bands were quantified using Gel-
Pro Analyzer software (Media Cybernetics). To control for equal
protein loading, membranes were also probed for actin and CSPG
values were normalized to actin (1:200, Millipore Bioscience
Research Reagents). Loading BSA (bovine serum albumin) was
used as a negative protein control.
Multiple immunofluorescence labeling. To assess the
phenotype of BrdU+ cells triple labelling immunofluorescence
was employed. The frozen slides of injured rats were blocked and
sequentially incubated with antibodies to mark two neural markers
as well as BrdU. Since some immunolabels are not specific to a
single cell type, we carefully selected triple immunolabeling
combinations to account for the possible overlap. A detailed list
of triple labelling immunostaining paradigms and the type of
primary antibodies used in our studies is provided in Tables 1 and
2. After incubation with each primary antibody, the slides were
washed in PBS three times and incubated with appropriate
secondary fluorescent Alexa 568, 488 or 647 (1:400; Invitrogen)
for 1 h. The slides were washed and coverslipped with Mowiol
mounting medium containing DAPI. For BrdU detection, the
tissue was pre-treated with 2 N HCl for 30 minutes at 37uC and
then washed with sodium borate buffer for 10 minutes followed by
two PBS wash before incubating with BrdU antibody.
Confocal microscopy and image analysis. We used
confocal microscopy to acquire images of the multi-fluorescent
labelled sections of the spinal cord. For quantification of cell
proliferation and differentiation, we examined one cross section of
the spinal cord between 2–3 mm rostral and caudal to the injury
center where all injured rats had an intact central canal and
ependymal layer (n=5–6 rats/group). We immunostained the
Figure 2. ChABC efficiently degrades CSPG in the injured spinal cord. (A, B) Confocal images of horizontal and cross sections of vehicle
treated spinal cords 12 days after SCI shows the intense expression of CSPGs (red) at the lesion site. (C, D) Treatment with ChABC at 4 days post-injury
for one week substantially reduced CSPGs deposits in the injured spinal cord. (E-G) Successful degradation of CSPGs was further confirmed by
pronounced appearance of chondroitin- 4-sulfate (C4S) in ChABC treated rats, which marks the tetrasaccharride linker region, or stub, that results
from ChABC enzymatic action. Inset image (E) represents the enlarged box in F that shows a magnified area of C4S immunoreactivity in ChABC
treated-injured rats. (H, I) Degradation of CSPGs by ChABC was confirmed by slot blotting. Quantification of CSPGs revealed a significant reduction in
CSPG level after ChABC treatment compared to the vehicle treated injured rats. This was supported by dramatic appearance of C4S immunoreactivity
in slot blotting in ChABC treated injured rats with no apparent immunoreactivity in vehicle group. (*p,0.05, n=3/group).
doi:10.1371/journal.pone.0037589.g002
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as shown in Table 1. Using images taken by confocal microscopy
at 256 primary magnification, we first counted the number of
BrdU-positive cells in 6 specified (368 mm6368 mm) per spinal
cord cross section. The selected fields included the ependymal/
subependymal region, dorsal and lateral columns and ventral gray
and white matter. Then, we calculated the percentage of colabeled
BrdU/cell markers for each triple labelling combination (summa-
rized in Table 2) in each spinal cord section. In all neuroanatom-
ical procedures, quantification was executed in a stereologically
unbiased manner by examiners blinded to the treatment groups
based on the previously described methods by our group [18,21].
Statistics and Randomization
Unbiased assessments were undertaken using appropriate
randomization and blinding in all experimental protocols.
Statistical analyses of intensity measurements and cell counts were
tested by one-way ANOVA comparing groups followed by post hoc
pairwise multiple-comparison testing by the Holm–Sidak method
or by Student’s t tests where two groups were compared. Data are
reported as means 6SEMs, and p,0.05 was considered signifi-
cant.
Results
Integrity of Ependymal Layer After Compressive SCI in
Rat
In this study, we used an aneurysm clip compression model of
SCI in the rat that closely mimics the hallmarks of human SCI
neuropathology [1,18,21,22,23]. We utilized a 23 g injury force
that results in an incomplete and moderately severe SCI. We have
extensively characterized and used this model in a number of
pharmacological and cellular therapeutic approaches
[1,18,20,21,25]. The rat SCI model results in inflammation,
astrogliosis, neuronal and oligodendroglial cell death, axonal
degeneration and demyelination that collectively lead to significant
spinal cord tissue loss and consequently the formation of a central
cavity in the chronic stage of injury (i.e. around four weeks after
SCI). Adult esNPCs mainly reside in the ependymal region lining
the central canal of the spinal cord [6,7,11] (Fig. 1B–D). Because
of their central localization in the spinal cord, they are directly
subjected to the cell loss after SCI. To characterize the integrity of
ependymal region in the rat compressive SCI, we performed
Hematoxylin/Eosin staining at various distances to the injury
center. At 12 days after SCI, the time point that we collected the
spinal cord tissues after treatments, we found an intact ependymal
region at approximately 2.5 mm rostral and caudal to the injury
center in all injured animals (Fig. 1). Accordingly, we undertook
our tissue phenotypic assessments in a distance between 2.5 to
3 mm from the injury center to ensure the presence of esNPCs in
the ependymal region in all animals.
CSPG Degradation after ChABC Treatment
We examined the effects of SCI-induced up-regulation of
CSPGs on the proliferation and differentiation pattern of spinal
cord precursors by using ChABC as we described previously [18].
We administered ChABC intrathecally at four days post SCI when
dense deposits of CSPGs accumulate in the ECM around the
spinal cord lesion [26]. We also chose to perform a delayed
subacute ChABC treatment in our studies in the light of evidence
that shows inhibition of CSPG synthesis immediately after injury
seems to exacerbate the outcomes of SCI by changing the
inflammatory response [27]. After eight days of sustained ChABC
treatment, using slot blot and immunohistochemistry analyses
against anti-chondroitin sulfate CS56 antibody that recognizes the
intact GAG side chains of CSPGs, we found significant reduction
in expression of CSPGs in ChABC-treated injured rats (n=6)
compared to the vehicle-treated counterparts (n=6) (Fig. 2).
Although ChABC did not entirely remove CSPGs, we found a 2.9-
fold reduction in the deposits of CSPGs around the SCI lesion
compared to the vehicle treated rats as evident by slot blot analysis
(Fig. 2H–I). We further confirmed enzymatic degradation of
CSPGs by immunohistochemistry against C4S, which marks the
tetrasaccharide linker region, or stub, that results from ChABC
enzymatic action. With no apparent endogenous C4S immuno-
reactivity in non-ChABC-treated injured animals (Fig. 2E–G), rats
treated with ChABC exhibited a pronounced expression of C4S in
the spinal cord tissue surrounding the lesion site (Fig. 1H–I).
The Effects of ChABC and Growth Factor Treatments on
Cellular Proliferation after SCI
We studied cell proliferation after SCI by using the BrdU
incorporation method. We administered BrdU daily during the
treatment period to label all dividing cell populations within the
injured spinal cord. Using confocal immunohistochemistry, we
found a significant number of BrdU labelled cells in the injured
spinal cord tissue (Fig. 3B) compared to the un-injured spinal cord
which only contained a very few BrdU
+ cells mostly around the
ependymal region (Fig. 3C). In the injured animals, BrdU
+ cells
were scattered in the entire cross sectional area of the spinal cord
tissue with a more pronounced density in the dorsal column
(Fig. 3A–B). We quantified the number of BrdU
+ cells in the cross
sections of the spinal cord under different treatments at 2.5–3 mm
point to the injury center both rostrally and caudally where all
animals had an intact central canal and ependymal region
(Fig. 1A). Our treatment groups consisted of: 1) vehicle-treated
(representing SCI baseline), 2) ChABC-treated, 3) GF-treated and
4) ChABC+GF treated. Using imaged taken from a confocal
microscope, we counted BrdU
+ cells in six defined areas of the
spinal cord that included ependymal/subependymal region and
central gray matter, ventral gray and white matter, as well as
lateral and dorsal white matter. Our cell quantification analysis
revealed an overall increase in the number of BrdU
+ cells in all
treatment groups (ChABC, GFs and ChABC+GFs) compared to
the vehicle-treated group in both rostral and caudal points to the
Figure 3. Increased number of proliferating cells after ChABC and GF treatments. (A–B) Representative cross sections of a subacutely
injured spinal cord at 12 days after SCI. At approximately 2.5 mm rostral point to the injury center, there was a significant number of BrdU labelled
cells within the injured spinal cord particularly in the dorsal column. (B) Higher magnification of the boxed area in (A) shows the presence of BrdU
labelled cells (red). (C–G) BrdU immunohistochemistry showed rare proliferative activity inside the spinal cord under normal condition (C). Our results
showed an increase in the number of BrdU-labeled cells (evidence of proliferation) after SCI under baseline condition (D). Interestingly, GF and/or
ChABC treatments were able to enhance cell proliferation in the areas distant to the injury center (E–G). The effect was significant for ChABC+GF
treated group in the rostral point and for all treatment groups in the zone caudal to the lesion epicentre compared to the vehicle group (H). *p,0.05,
n=6/group.
doi:10.1371/journal.pone.0037589.g003
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+ cells was
significant for all treatment groups caudal to the lesion epicentre.
In the rostral regions, although all groups showed a trend for
increased number of proliferating cells in the spinal cord, only the
value for ChABC+GFs group reached the level of significance
level (p,0.05, Fig. 3H).
ChABC and Growth Factor Treatments Increase the
Proliferation of Nestin Positive esNPCs After SCI
After SCI, we found a dramatic expression of nestin in cells
residing in the ependymal layer and subependymal region,
whereas no apparent nestin expression was present in the un-
injured spinal cord (Fig. 4A–B). We next examined whether
ChABC and/or GFs treatments enhanced the proliferation of
nestin positive precursor cells in the spinal cord. Because reactive
astrocytes also express nestin after SCI, we employed triple
labelling staining combination against nestin/GFAP/BrdU to
distinguish proliferating esNPCs from reactive astrocytes. We
considered activated esNPCs as BrdU+/Nestin+/GFAP- and
proliferating reactive astrocytes as BrdU+/Nestin+/GFAP+
(Table 2). Using this criterion, we found a significant increase in
the number of newly proliferating esNPCs (BrdU+/Nestin+/
GFAP-) cells in all treatment groups in comparison to the vehicle-
treated rats both in rostral and caudal points to the injury center
(Fig. 4I, 4J).
Combination of ChABC and Growth Factors Promote
Oligodendrocyte Differentiation After SCI
We next examined the phenotype of BrdU labelled cells with
multiple fluorescent labelling in the spinal cord sections of the rats
treated with vehicle, ChABC, GFs and ChABC+GFs. To account
for the possible overlapping of expression that exists among
different cell types, we developed triple labelling paradigms to
accurately identify the phenotype of BrdU labelled cells. Under
basal injury conditions (i.e. vehicle-treated group), approximately
50% of BrdU labelled cells were GFAP+ (Fig. 5). Interestingly, we
found a reduction in the number of newly generated astrocytes
marked as GFAP+/BrdU+ under all treatment conditions
compared to the vehicle-treated rats. This reduction was
statistically significant for ChABC and ChABC+GFs in both
rostral and caudal points to the injury center (Fig. 5A–E). Of note,
our immunolabeling studies showed the absence of GFAP
expression in the ependymal cells, which is in agreement with
previous findings by Frisen group [7] that also showed the lack of
GFAP expression in genetically labelled ependymal cells sur-
rounding the central canal. Although GFAP positive astrocytes
were closely surrounding the ependymal layer and sending their
cell processes into the region, no GFAP expressing cell was
observed inside the ependymal layer.
The decrease in the number of new astrocytes was accompanied
by an increase in the number of BrdU+ cells within the
oligodendroglial lineage. Using triple fluorescent labelling for
Olig2/GFAP/BrdU, we found a significant increase in the
number of Olig2+/GFAP2/BrdU+ cells after treatment with
GF and ChABC+GFs (Fig. 5F–K). Olig2 transcription factor has
been shown to be also expressed by reactive astrocytes in some
regions of the spinal cord after injury; therefore we used double
labelling for Olig2 and GFAP to accurately identify newly
generated oligodendrocytes marked as Olig2+/GFAP- among
BrdU+ cells. We further determined the percentage of oligoden-
drocyte precursor cells (OPCs) and mature oligodendrocytes
among the Olig2+/GFAP- population. We employed NG2/
Olig2/BrdU and APC/Olig2/BrdU labelling combinations to
distinguish OPCs from mature oligodendrocytes, respectively, as
we previously described [18,21,28]. Our quantitative assessments
revealed the presence of both immature and mature oligodendro-
cytes among the BrdU labelled cells with 2–3 folds more new
OPCs (NG2+/Olig2+/BrdU+) than mature oligodendrocytes
(APC+/Olig2+/BrdU+) oligodendrocytes (Fig. 6). Interestingly,
the new NG2+/Olig2+ OPCs were only a small subpopulation of
the total NG2+/BrdU+ cells after SCI. Under basal SCI
condition, although we found that approximately 35–45% of the
BrdU+ cells were expressing NG2 in 3 mm caudal and rostral
points to the injury, only about 5–10% of the NG2+/BrdU+ cells
were NG2+/Olig2+/BrdU+ OPCs. To determine the phenotype
of the remaining NG2+ cells, we conducted triple immunostaining
to include markers for macrophages/microglia as well as vascular
endothelial cells. Our quantitative assessments indicated the
presence of newly generated NG2+ endothelial cells (NG2+/
Reca1+/BrdU) and macrophages/microglia (NG2+/Iba1+/
BrdU+) under all experimental conditions suggesting that NG2+
cells represent multiple lineages in the spinal cord (Fig. 7).
Interestingly, we found that ChABC and/or GF treatments
significantly increased the number of newly generated endothelial
cells after SCI (Fig. 7G–L) suggestive of a potential for these
treatments in promoting angiogenesis. While both GFs and
ChABC had competitive effects on endothelial cell proliferation,
only ChABC and ChABC+GF treatments exerted a significant
effect on attenuating the proliferation of macrophages/microglia
in the penumbra regions of the SCI lesion (7A–F).
Combination of ChABC and Growth Factors Attenuate
Astrogliosis and Inflammation Around the SCI Lesion
We further investigated the influence of ChABC and GF
therapy on the evolution of reactive astrogliosis and activation of
microglia/macrophages at the lesion site. Our quantitative slot
blot analysis indicated a positive trend in reducing the expression
of GFAP and Iba-1, marking astrocytes and macrophages/
microglia, respectively, in all treated groups (Figure 8). However,
only the group with ChABC+GF treatments showed a significant
decrease in GFAP expression at the SCI center (Fig. 8). We also
found a significant reduction in the presence of macrophages/
Figure 4. ChABC and GFs enhance the proliferation of NPCs after SCI. (A–B) Confocal images showing ependymal region in the central canal
(CC) of the spinal cord. After SCI (B), there was a significant increase in the expression of nestin (red) in the ependymal/subependymal cells compared
to the un-injured spinal cord with no apparent nestin immunostaining (A). SCI also induces the proliferation of ependymal cells evident by BrdU
labelling (green). (C–G) Representative confocal images of the ependymal region of a rat treated with ChABC+GFs. Triple labelling for Nestin/GFAP/
BrdU was used to identify proliferating/activating NPCs marked as BrdU+/nestin+/GFAP-. This immunostaining combination was used to distinguish
nestin+ NPCs from nestin positive reactive astrocytes after SCI (Table 2). Normal astrocytes (GFAP+) and reactive astrocytes were mostly confined in
the subependymal layer whereas Nestin+/GFAP- cells resided in the ependymal layer (C–G). We found BrdU+/nestin+/GFAP- that were migrating
away from the ependymal layer to reside in parenchyma (arrows in G) Our quantitative confocal immunohistochemistry revealed a significant
number of BrdU+/nestin+/GFAP- (in all treatment groups compared to the vehicle-injured group particularly around the central canal at both 3 mm
rostral and caudal points to the injury center (H-I, *p,0.05, n=6/group). Note: Our immunolabeling showed the absence of GFAP expression in
ependymal cell. Although GFAP positive astrocytes were closely surrounding the ependymal layer and sending their process into the region, no GFAP
expressing cell was observed inside the ependymal layer.
doi:10.1371/journal.pone.0037589.g004
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ChABC+GFs (Fig. 8).
Discussion
In the present study, to our knowledge, we demonstrate for the
first time that inhibiting CSPGs combined with growth factor
treatment enhances the regenerative response of endogenous
spinal NPCs (esNPCs) in a clinically relevant model of compres-
sive/contusive rat SCI. This strategy that included the adminis-
tration of ChABC and a cocktail of growth factors bFGF, EGF
and PDGF-AA increased the proliferation of esNPCs, reduced the
number of new astrocytes and promoted the differentiation of
esNPCs along an oligodendroglial lineage, a prerequisite for
remyelination. Furthermore, the ChABC and GF therapy
enhanced the response of non-neural cells by increasing the
generation of new vascular endothelial cells and decreasing the
number of proliferating macrophages/microglia after SCI. Col-
lectively, our data provide strong evidence that the activity of
esNPCs is hindered in their post-SCI niche and approaches to
improve their environment would enhance the regenerative
potential of esNPCs for the repair of SCI.
Following SCI, loss of oligodendrocytes [29] results in
demyelination that not only leads to axonal dysfunction but also
further impairs the integrity of surviving injured axons
[1,20,25,30,31]. Emerging evidence from our group and others
has established the promising potential of transplanting NPCs
derived from the adult CNS tissues in oligodendrocyte replace-
ment and remyelination associated with functional recovery after
SCI [18,21,32,33,34]. Existence of resident NPCs in the ependy-
ma of the spinal cord with the capacity to generate new glial cells
[4,6,10,35] has raised an exciting possibility for enhancing
endogenous repair after SCI. Interestingly, recent evidence shows
that the esNPCs indeed generate more oligodendrocytes than
astrocytes under normal conditions in the spinal cord [6,7].
However, despite this capacity, the majority of esNPCs differen-
tiate into astrocytes after SCI and only a smaller number give rise
to oligodendrocytes [6]. In a dorsal funiculi SCI by using genetic
labelling of esNPCs in the ependyma, Frisen group has shown that
the newly generated astrocytes become activated and recruited to
the site of SCI and contribute to astrogliosis and glial scar [6]. This
evidence suggests that the response of esNPCs to SCI is not
supportive; and on the contrary is inhibitory to the regenerative
activities inside the injured spinal cord. For example, the
inhibitory influence of astrogliosis on limiting axonal regeneration
and plasticity after SCI is very well established
[3,16,17,36,37,38,39,40]. Given this, it is therefore critical to
optimize the behaviour of esNPCs in their post-SCI environment
not only to promote endogenous repair process, but also to reverse
the otherwise non-constructive response of esNPCs after SCI.
Previous studies have shown that in vivo administration of EGF
and bFGF, two growth factors essential for the expansion and
maintenance of NPCs in vitro; increases the proliferation of
ependymal cells after SCI [41,42]. However, despite their
increased activity, the generation of new oligodendrocytes from
esNPCs was unaffected after SCI [41,42], suggesting that further
optimization is needed to support oligodendrocyte differentiation.
Another study showed that combined overexpression of Neuro-
genin2 and Mash1 enhanced the generation of new neurons and
oligodendrocytes at the expense of astrocytes after SCI [43];
however this strategy did not afford to support the maintenance of
the newly generated oligodendrocytes. This observation implicates
the inhibitory influence of SCI microenvironment on the
integration and survival of newly differentiated cells within the
injured spinal cord. Our group has recently demonstrated a key
role for the SCI-induced up-regulation of CSPGs in the glial scar
on the survival and integration of transplanted NPCs in vivo [18].
We showed that degradation of CSPGs with ChABC significantly
improved the migration of transplanted NPCs from the implan-
tation sites to the SCI lesion. ChABC treatment also enhanced the
long-term survival of transplanted NPCs and aided in their
integration with the spinal cord axons. We combined ChABC with
administration of EGF, bFGF and PDGF-AA to enhance the
survival of transplanted NPCs and direct their fate into
oligodendrocytes. PDGF-AA is growth factor secreted by astro-
cytes in the CNS that promotes the proliferation of neural
progenitors and stimulates the differentiation of oligodendrocytes
[44,45], and is also implicated in the survival of and migration of
newly formed oligodendrocytes [46,47]. Moreover, PDGF, in
synergy with bFGF, regulates the proliferative response of adult
oligodendrocyte progenitors [48,49,50]. In our transplantation
studeis, combination of these growth factors afforded to direct the
majority of transplanted NPCs (about 80%) to differentiate along
an oligodendroglial lineage [18]. Interestingly, although ChABC
alone did not show any additional benefits to the effects of growth
factors in enhancing the differentiation of oligodendrocytes, it
markedly increased the migration, survival and integration of
transplanted NPCs compared to the groups that only received
growth factors. Our data, therefore; indicate the importance of
combinatorial approaches aimed at enhancing the proliferation
and differentiation of NPCs as well as optimizing their integration
within the injured spinal cord.
In the present study, we examined the combined effects ChABC
and GFs on the cellular response of esNPCs after SCI. We
administered ChABC at day 4 following SCI, when dense deposits
of CSPGs have begun to accumulate around the SCI lesion. We
also combined ChABC treatment with a cocktail of EGF, bFGF
and PDGF-AA. We undertook continuous BrdU incorporation
during the treatment period to label proliferating cells. Here, we
focused on characterizing the response of esNPCs to ChABC and
GFs at the end of treatments (i.e. eight days after the treatments or
12 days after SCI). Overall, we found a significant increase in the
number of proliferating cells in the ChABC treated group
compared to the vehicle-treated counterparts. The effect of
ChABC alone was comparable to the effects of GF treatment
alone. Importantly, the increased number of BrdU positive cells
reflected an increase in the number of activated esNPCs (Nestin+/
GFAP2/BrdU+) after GF and/or ChABC treatments. Interest-
Figure 5. ChABC and GFs reduce astrocyte differentiation and promote the formation of new oligodendrocytes after SCI. (A–C)
Representative confocal images showing BrdU labelled astrocytes that were newly generated after treatments in the injured spinal cord. (D–E) Our
cell quantification for BrdU+/GFAP+ profiles (arrows in C) showed a significant decrease in the number of new astrocytes after treatment with ChABC
and ChABC+GFs compared to the vehicle group in the 3 mm rostral point to the injury center. We also found a significant reduction in astrocyte
proliferation in all treatment groups at 3 mm caudal distance to the injury center relative to the vehicle group (D, E, *p,0.05, n=6/group). (F–H)
Representative confocal images show triple labelling for BrdU/Olig2/GFAP (arrows). To quantify BrdU labelled cells with oligodendrocyte phenotype,
we only quantified Olig2+/GFAP2 to exclude Olig2 expressing reactive astrocytes. Interestingly, there was a significant increase in the number of
newly generated oligodendrocytes (arrows) in GFs and ChABC+GF in comparison to the vehicle group at both rostral and caudal points to SCI center
(*p,0.05, n=6/group).
doi:10.1371/journal.pone.0037589.g005
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PLoS ONE | www.plosone.org 11 May 2012 | Volume 7 | Issue 5 | e37589Figure 6. ChABC and GF treatments enhance the proliferation and differentiation of oligodendrocyte precursor cells (OPCs) after
SCI. (A–D) Representative confocal images showing triple immunostaining for NG2, Olig2 and BrdU in injured spinal cord. To accurately identify OPCs
among BrdU+ cells, we used double labelling for Olig2 and NG2 (Table 2). (E–F) Our quantification for BrdU+/Olig2+/NG2+ (arrows in D) revealed a
significant increase in the number of OPCs after ChABC+GF treatments relative to vehicle (approximately a three-fold increase in 3 mm rostral point
and a four-fold increase in 3 mm caudal point). (G–J) We also used BrdU/Olig2/APC immunostaining combination to mark and quantify mature
oligodendrocytes after ChABC and GF treatments. Our analysis showed a positive trend for an increase in the number of newly generated mature
oligodendrocytes under ChABC and/or GF treatments compared to vehicle at both 3 mm rostral and caudal points to the injury center (K–L).
However, this increased level did not reach a statistically significant level. *p,0.05, n=6/group.
doi:10.1371/journal.pone.0037589.g006
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PLoS ONE | www.plosone.org 12 May 2012 | Volume 7 | Issue 5 | e37589Figure 7. ChABC and GF treatments attenuate the proliferation of microglia/macrophages and promote the generation of new
endothelial cells after SCI. (A–D) Representative confocal images of BrdU+/NG2+ macrophages/microglia marked with Iba-1 in the injured spinal cord
(arrows). (E–F) Under baseline SCI condition, macrophages/microglia comprised about 25% and 17% of BrdU+/NG2+ cells in rostral and caudal points to the
injury center, respectively. After treatment with ChABC and/or GFs, we found a reduction in the number of BrdU+/NG2+/IbA-1+ cells that was statistically
significant for ChABC and ChABC+GFs treatment groups relative to the vehicle group. (G–J) Representative confocal images show newly generated endothelial
c e l l sm a r k e db yR e c a - 1a n dN G 2a m o n gB r d U + cells. Reca-1 positive endothelial cells comprised a subpopulation of proliferating NG2+ cells after SCI (J). (K–L)
Quantification of BrdU+/NG2+/Reca-1+ cells showed a significant number of newly generated endothelial cells after treatment with ChABC and/or GFs at both
rostral and caudal points to the injury center compared to the vehicle group. *p,0.05, n=6/group.
doi:10.1371/journal.pone.0037589.g007
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astrocytes and increased the generation of new oligodendrocytes
after SCI. Although ChABC and GFs exerted similar effects on
attenuating astrocytic differentiation, the presence of GFs in this
therapeutic combination was indispensable in directing the fate of
esNPCs toward an oligodendroglial lineage (BrdU+/Olig2+/
GFAP-). This observation is also consistent with our previous
studies in NPC transplantation approaches that showed no
significant effect of ChABC on oligodendrocyte differentiation of
transplanted NPCs after SCI [18,21]. This evidence suggests that
although ChABC does not appear to directly affect oligodendro-
cyte differentiation of esNPCs, it reduces their differentiation into
astrocytes. While the exact molecular mechanisms by which
CSPGs influence the fate of esNPCs after SCI require further
elucidation, it seems that up-regulation of CSPGs by activated
Figure 8. ChABC and GF treatments reduce the injury-induced astrogliosis and inflammation at the lesion site. (A–F) Cross sections of
the spinal cord at the lesion site from vehicle and ChABC+GF treated animals show immunostaining for astrocytes (marked by GFAP) and
macrophages/microglia (marked by OX42). Confocal images clearly show an overall reduction in the expression of GFAP and OX42 particularly in the
surrounding paranchymal region in ChABC+GFs treated spinal cords relative to the vehicle group. Our immunoblotting analyses indicated a
significant reduction in GFAP and Iba-1(macrophages/microglia) at the lesion site in ChABC+GF and ChABC and ChABC+GF treatments, respectively.
*p,0.05, n=4/group.
doi:10.1371/journal.pone.0037589.g008
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astrogliosis.
In our studies, in agreement with previous reports [5,51,52], we
found a significant number of newly generated NG2 expressing
cells. NG2 cells represent a heterogeneous population after SCI
that include oligodendrocyte precursor cells (OPCs), macrophag-
es/microglia and endothelial cells [9,53,54,55]. Although the
overall number of NG2 expressing cells remained unchanged in
ChABC and/or GF treated groups compared to the vehicle
treated group, we found a significant difference in the phenotype
of NG2 cells under different treatments. Animals treated with
ChABC+GFs, showed a significantly increased number of NG2+/
Olig2+/BrdU+ cells which suggest the synergistic effects of
ChABC and GFs in promoting differentiation of esNPCs into
OPCs after SCI. We also observed a significant increase in the
number of newly generated endothelial cells under both GFs and
ChABC treatments compared to the baseline injury with no
further benefits of their combination. On the contrary, the number
of NG2 expressing macrophages/microglia was significantly
reduced only in the groups treated with ChABC and ChABC+GFs
with no additional effects from GF therapy. Our assessment of SCI
epicentre also revealed a reduction in the presence of macrophag-
es/microglial after ChABC and ChABC+GFs treatments. This
evidence suggests a role for ChABC treatment in attenuating the
inflammatory response after SCI. Further elucidation is required
to understand the mechanisms by which ChABC affects the
activation of inflammatory cells. We also found a positive trend in
increased number of new mature oligodendrocytes (APC+/
Olig2+/BrdU+) under GFs and/or ChABC treatments; however,
it did not reach a significant level at 12 days post-SCI. It is possible
that either these treatments are not sufficient to fully support
oligodendroglial maturation in the spinal cord or more time is
needed for transitioning from an OPC phenotype to a mature
myelinating oligodendrocyte phenotype. Long-term investigations
are required to determine whether these treatments can promote
oligodendrocytes maturation after SCI. As expected, no neuronal
differentiation was observed among BrdU labelled cells which is in
complete agreement with our previous studies and those of others
that show NPCs in the environment of adult spinal cord are mostly
capable of generating glial cells [6,7,18,21]. Apparently, admin-
istration of ChABC and GFs did not afford to stimulate
neurogenesis.
Conclusions
In the present work, we have identified another mechanism by
which CSPGs hinder the repair of SCI. For a number of years,
CSPGs were mainly considered inhibitory for axonal regeneration.
Here, we report for the first time that perturbing the inhibitory
properties of CSPGs in the post-SCI environment combined with
the administration of growth factors EGF, bFGF and PDGF-AA
significantly enhanced the response of endogenous spinal cord
NPCs. This strategy effectively increased the proliferation of
esNPCs and enhanced their differentiation into OPCs similar to
their differentiation pattern seen under normal condition. Our
results also show that perturbing CSPGs and increasing the level of
GFs has the potential to positively improve the microenvironment
of SCI by reducing inflammation and facilitating the reconstruc-
tion of compromised vasculature after SCI. Our data provide
support for the promising effects of this combinatorial approach,
which addresses several key pathomechanisms, for the repair of
SCI.
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